Skip to main content
Premium Trial:

Request an Annual Quote

Diversa, Glaxo Wellcome Pen Deal to Jointly Research Molecules

NEW YORK, Dec 12 - Diversa said Tuesday it had reached an agreement with Glaxo Wellcome to jointly research novel small molecules in Diversa’s PathwayLibraries.

Under the terms of the non-exclusive deal, Diversa and Glaxo Research and Development, a subsidiary of Glaxo Wellcome, will identify and screen molecules in the database for specific pharmaceutical activity.

Glaxo Wellcome will receive exclusive worldwide rights to molecules selected for commercialization. Diversa did not disclose financial terms of the deal.

Diversa's PathwayLibraries holds small molecule drug candidates produced by collections of gene pathways from environmental sources. Complex recombinant libraries are generated from uncultivated microorganisms with the company’s own methods for extracting DNA from the environment and by applying patented normalization methodologies.

The company said that its approach helps to speed up drug discovery and to identify gene products from the many microbes that remain unexplored.

" This collaboration with Diversa gives Glaxo Wellcome the potential to evaluate a new source of chemical diversity with the potential to generate novel leads for important therapeutic targets," said Allan Baxter, group discovery director at Glaxo Wellcome, said in a statement.

Earlier this month, Diversa said it had signed a “multi-year, cross-royalty” collaboration with Celera to sequence the genomes of extremophiles in its libraries.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more